Cadaver Skin Booster: Who Died for Your Glow?

The latest conversation in Korean aesthetic medicine begins with an unsettling ingredient: skin donated by someone who has died. Processed into an injectable material, this tissue now appears on treatment menus promising improvements in texture, elasticity and firmness. The cadaver skin booster has attracted commercial investment, medical curiosity and ethical scrutiny, placing tissue donation at the center of a rapidly developing beauty business.

What Is a Cadaver Skin Booster?

A cadaver skin booster is an injectable preparation made from donated human dermis, the skin layer beneath the epidermis. South Korean biotechnology company L&C Bio markets a product called Elravie Re2O, developed from human acellular dermal matrix, abbreviated hADM.

The dermis naturally contains an extracellular matrix, or ECM: a network of proteins and other substances surrounding skin cells. Collagen provides structural support, elastin contributes flexibility, and other molecules help organize tissue and retain water. This framework plays an important role in skin structure.

Manufacturers obtain donor tissue through tissue banks, screen and process it, then remove cellular material in a procedure called decellularization. The remaining matrix undergoes further processing into particles that can be prepared for injection. Careful screening and processing remain essential for human donor materials. The finished material contains structural components derived from the donor's skin. It consists of processed tissue, with donor cells removed.

The proposed treatment mechanism involves placing this matrix within the recipient's dermis, where it may support interactions between local cells and surrounding tissue. Scientists are investigating how the material behaves after administration and how long its effects persist.

The Numbers Behind the Rising Demand

Re2O entered the South Korean market in late 2024 and gained momentum during 2025 and 2026. Reporting in October 2026 placed first-half sales above $17 million and estimated its share of the human-tissue booster segment at 60–70%.

L&C Bio's financial filings offer another indicator. Its standalone revenue reached 55.4 billion Korean won during the first half of 2026, representing 78.4% year-on-year growth. The company attributed an part of that performance to expanding Re2O sales. These figures measure different things: product revenue, category share and overall company performance.

The company has also pursued overseas distribution, including an announced American agreement valued at a minimum of $60 million. Commercial agreements indicate expansion ambitions; access to a particular market still depends on its regulatory requirements.

South Korean biotechnology company Hans Biomed has also entered the human tissue-derived skin booster market with CellREDM. In 2026, the company partnered with aesthetics specialist Hugel to expand its domestic distribution, signaling growing commercial interest in regenerative injectables across the Korean beauty industry.

Where Clinics Offer the Treatment

Re2O appears on menus at several Seoul aesthetic practices. Yaan Clinic in Gangnam advertises a full-face session at approximately 790,000 won. Liftique Dermatology in Sinsa lists a session at 700,000 won before value-added tax, with packages for repeated appointments.

The procedure typically involves consultation, assessment of skin concerns, local anesthesia when appropriate, and administration with a needle or cannula. Clinics describe treatment appointments lasting roughly twenty to thirty minutes, although protocols and injection quantities vary.

Published clinic prices indicate commercial availability. They also remind prospective patients to confirm the practitioner's medical qualifications, the precise product, treatment indication and final cost during consultation.

Why the Cadaver Skin Booster Appeals to Beauty Consumers

The cadaver skin booster sits within South Korea's established injectable skincare culture, where consumers encounter treatments advertised for hydration, fine lines, pores and skin quality. Its distinctive proposition concerns the extracellular matrix, a familiar concept in regenerative medicine and tissue reconstruction.

L&C Bio already works with processed human tissue for medical applications. That technical experience provides a foundation for manufacturing and marketing the aesthetic product. In clinics, scientific terms such as collagen scaffold, tissue remodeling and regeneration help communicate the proposed mechanism.

Meanwhile, international beauty tourism and social media amplify curiosity about emerging Korean procedures. Public interest also reflects the extraordinary origin of the material, which combines sophisticated processing technology with difficult questions about the human body.

What to Check Before Considering Treatment

A cadaver skin booster involves an invasive injection of human-derived material. Consultation with a qualified physician should cover donor sourcing, tissue screening, product processing, local regulatory classification and the evidence supporting the intended indication.

Potential complications include bruising, swelling, infection, inflammatory reactions, nodules and vascular injury associated with injectable procedures. Patients should discuss medical history, allergies, previous facial treatments, aftercare and access to urgent assessment if concerning symptoms develop.

Consent raises another important issue. Human tissue donation supports reconstructive medicine and treatment of serious injuries. Commercial cosmetic use introduces questions about whether donors understood the eventual destination of their tissue, how consent was recorded and how companies communicate that information.

These unresolved issues also make careful public reporting essential as the category enters new markets and reaches international patients. The cadaver skin booster therefore represents a revealing moment in beauty innovation. Its future will depend on transparent sourcing, rigorous clinical investigation and responsible oversight, alongside consumers' growing curiosity about treatments derived from the human body's own architecture.